Effect of Favipiravir on some epidemic infections: A mini review

Abstract Favipiravir is a modern antiviral drug that can be used in developing viral pandemics, such as the Ebola virus, H1N1 flu, Lassa fever, and haemorrhagic fever outbreaks Argentina 2009. A. Chain conclusion transformed to favipiravir-RTP inserted into RNA strand elongating. Then, since favipiravir acts chain terminator, elongation slows down at incorporation site of does not continue. The proofreading enzyme cannot repair this complex RNA-favipiravir it will discarded excessive RNA, which causes extinction genome. Mutagenesis with lethal consequences Ribavirin elongating process until completion. single several ribavirin sites incorporates or mRNA for production proteins. Due onto mismatching base pairs (transition mutation) occur. Translation mutated then cause mutations sequence amino acid residues protein, result impaired protein function. Viral proteins have lost their function are unable replicate generate infectious particles, virus no longer infectious. As result, mutagenesis ends infection different way than termination. Favipiravir’s clinical trial against virus-infected patients has yet been formally approved, further research required. Favipiravir, on other hand, poses risk embryo toxicity teratogenicity. Japanese Ministry Health, Welfare Labor approved medication recommendations more use August 15, 2014, when they due epidemic West Africa. aim review investigate potential impact infections espectially RNA-virus infections, according previous published investigations, thus encourage rapid approval interesting antivirus emergencies.